ArticleScientific reports2025
PDualNet: a deep learning framework for joint prediction of Parkinson's disease progression subtype and MDS-UPDRS scores.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Parkinson's disease is one of the most common and complex neurodegenerative diseases, characterized by remarkable motor and cognitive decline. As it is a highly heterogeneous disorder, i.e., the specific symptoms, their severity, and their progression rate manifest significant interpersonal variability, multiple progression subtypes can be defined. The identification and prediction of these subtypes is crucial for understanding the disease's state and future trajectory, advancing prognostic accuracy and personalized treatment planning. At the same time, the ability to predict future MDS-UPDRS scores, provides an objective assessment of symptoms, supporting clinicians in tracking disease progression and evaluating treatment efficacy. To address both critical objectives, we introduce PDualNet, a novel dual-task framework that jointly models and predicts the disease progression and severity based on longitudinal clinical patient data. Our approach involves two key components: (i) an unsupervised module that maps the single-visit data of each patient, onto a "Single-Visit Embedding (SiVE) space", and (ii) a supervised part, that utilizes the pre-trained SiVE embeddings to learn a compact representation of the longitudinal data of each patient, representing the "Disease State Embeddings (DiSE)". These embeddings drive two parallel decoders: one predicting the progression subtype, and the other forecasting the future MDS-UPDRS I-III scores. After analysing patient visit data from up to six years after baseline, each consisting of 89 clinical features, we trained and evaluated PDualNet on 579 participants from the Parkinson's Progression Markers Initiative. The resulting model, demonstrated remarkable performance on both classification and regression tasks, while additional validation on 490 participants from the Parkinson's Disease Biomarkers Program cohort, confirmed its robust performance and strong generalization capabilities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.